Septic Shock Clinical Trial
Official title:
Hemodynamic Effects of Low Doses of Arginine Vasopressin in Early Septic Shock Stage
Vasopressin is a vasopressor used in patients with septic shock. However, its systemic hemodynamic effects and its microcirculation effects are not completely known and understood. This study aimed to evaluate the effect of exogenous vasopressin on sublingual microcirculation using the sidestream dark field technique and to correlate it with its systemic effects. To this prospective interventional study, patients with septic shock were included during the first 48 hours of use of catecholamine vasopressors, admitted to the intensive care unit of a university hospital. Vasopressin was administered at 0.04 U / min for one hour. Systemic hemodynamic measurements were obtained immediately before and 1 hour after vasopressin. In addition, images of sublingual microcirculation were collected through sidestream dark field technology. Further analysis with specific software was done after.
Immediately before vasopressin infusion, fluid responsiveness was evaluated by delta PP
(ΔPP) with ΔPP module attached to the monitor (DX 20x20, Dixtal, São Paulo, Brazil).
Continuous sedation was maintained to control spontaneous ventilatory efforts. ΔPP > 13%
receive crystalloid (Ringer's lactate or normal saline 0.9%) challenges until the ΔPP were
below this value. Patients in whom was not possible to measure ΔPP, received crystalloid
aliquots of 500 ml until there was no increase in cardiac output greater than 10%.
Vasopressors were used to maintain mean arterial pressure above 65 mmHg. The fraction of
inspired oxygen was adjusted to maintain oxygen saturation between 92-94%.
Thirty minutes after initial stabilization (the pre-vasopressin), all hemodynamic and
respiratory measurements were obtained (pre-vasopressin), namely mean arterial pressure
(MAP), heart rate (HR), right atrial pressure (RAP) , mean pulmonary artery pressure (MPAP),
occluded pulmonary artery pressure (OPAP), cardiac index (CI), stroke index (SI), systemic
vascular resistance index (SVRI), pulmonary vascular resistance index (PVRI). Samples were
collected for blood gas analysis and arterial and mixed venous blood lactate.
Direct analysis of the sublingual microcirculation was done at that time by videomicroscopy
obtained by SDF (Microscan; MicroVision Medical, Amsterdam, Netherlands), following the
protocol previously described. Briefly, after removal of secretions, the lens of SDF was
placed in the sublingual space without exerting any pressure. All images were obtained by a
qualified physician using the recommended techniques to ensure image quality. We obtained
three sequential images of high quality stable for at least 20 seconds, of both sides of the
tongue while avoiding artifacts pressure. All images were captured using a notebook and a
video converter analog / digital (ADVC110, Canopus Co, San Jose, California).
After obtaining baseline data, vasopressin was infused at fixed dose of 0.04 U / min. After
one hour of vasopressin(post-vasopressin), the same variables were collected. If required,
the adrenergic vasopressors infusion was adjusted during the study to maintain the target
MAP from 65 to 70 mmHg. If patients were receiving dobutamine, its dose was kept constant
during the study procedures. If fluid replacement or adjustment of ventilatory parameters or
sedation were needed during the study, the patient was excluded.
All images were subsequently analyzed using the AVA 3.0 ® software (Microvision Medical,
Amsterdam, Netherlands), considering only vessels with a diameter less than 20 micrometers.
A blinded investigator analyzed all the images in a random order. The microcirculatory flow
index (MFI), the total vascular density (TVD), the proportion of perfused vessels (PPV), the
perfused vessel density (PVD), and the heterogeneity index (HI) were calculated.
Briefly, the MFI is calculated from the imaginary division of the image captured and
stabilized into four quadrants. Its calculation is the average of the subjective evaluation
of the flow in the four quadrants, quantified 0-3, where 0 corresponds to absent flow, 1
intermittent flow, 2 and 3 sluggish flow and continuous flow, respectively. TVD is
calculated from the assumption that it is proportional to the number of vessels crossing
three horizontal lines and three vertical equidistant arbitrary placed in the overlay image.
The program computes the number of vessels crossing the lines and vessels and the total is
divided by the lines length. Perfusion subjective evaluation was done in each vessel,
graduated from 0 to 3 (absent, intermittent, sluggish or continuous). The PPV is calculated
from the total number of vessels counted in the TVD subtracted not perfused vessels (those
with flow 0 or flow 1), according to the formula: PPV = TVD - not perfused vessels / TVD
x100. The PVD is obtained by multiplying TVD and PPV. The HI is calculated from the
difference between the highest and lowest MFI found in three images captured in each moment
(before and after vasopressin), according to the formula: HI = highest MFI - lowest MFI /
MFI average.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03649633 -
Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock
|
Phase 1/Phase 2 | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Completed |
NCT05629780 -
Temporal Changes of Lactate in CLASSIC Patients
|
N/A | |
Recruiting |
NCT04796636 -
High-dose Intravenous Vitamin C in Patients With Septic Shock
|
Phase 1 | |
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Recruiting |
NCT05066256 -
LV Diastolic Function vs IVC Diameter Variation as Predictor of Fluid Responsiveness in Shock
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 | |
Not yet recruiting |
NCT04516395 -
Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae
|
N/A | |
Recruiting |
NCT02899143 -
Short-course Antimicrobial Therapy in Sepsis
|
Phase 2 | |
Recruiting |
NCT02676427 -
Fluid Responsiveness in Septic Shock Evaluated by Caval Ultrasound Doppler Examination
|
||
Recruiting |
NCT02565251 -
Volemic Resuscitation in Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT02580240 -
Administration of Hydrocortisone for the Treatment of Septic Shock
|
N/A | |
Completed |
NCT02638545 -
Hemodynamic Effects of Dexmedetomidine in Septic Shock
|
Phase 3 | |
Terminated |
NCT02335723 -
ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber
|
N/A | |
Not yet recruiting |
NCT02547467 -
TOADS Study: TO Assess Death From Septic Shock.
|
N/A | |
Completed |
NCT02306928 -
PK Analysis of Piperacillin in Septic Shock Patients
|
N/A | |
Completed |
NCT02204852 -
Co-administration of Iloprost and Eptifibatide in Septic Shock Patients
|
Phase 2 |